At the end of the latest market close, ASLAN Pharmaceuticals Limited (ASLN) was valued at $1.63. In that particular session, Stock kicked-off at the price of $1.65 while reaching the peak value of $1.90 and lowest value recorded on the day was $1.6433. The stock current value is $1.80.
Recently in News on November 19, 2020, ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference. ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
ASLAN Pharmaceuticals Limited had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.8500 on 01/17/20, with the lowest value was $0.8300 for the same time period, recorded on 03/19/20.
ASLAN Pharmaceuticals Limited (ASLN) full year performance was -31.30%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ASLAN Pharmaceuticals Limited shares are logging -78.00% during the 52-week period from high price, and 116.87% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.83 and $8.18.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1710701 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ASLAN Pharmaceuticals Limited (ASLN) recorded performance in the market was -11.33%, having the revenues showcasing 21.62% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 57.35M.
ASLAN Pharmaceuticals Limited (ASLN) in the eye of market guru’s
During the last month, 2 analysts gave the ASLAN Pharmaceuticals Limited a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.7026, with a change in the price was noted +0.0200. In a similar fashion, ASLAN Pharmaceuticals Limited posted a movement of +1.12% for the period of last 100 days, recording 214,947 in trading volumes.
ASLAN Pharmaceuticals Limited (ASLN): Stocks Technical analysis and Trends
Raw Stochastic average of ASLAN Pharmaceuticals Limited in the period of last 50 days is set at 36.54%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 73.49%. In the last 20 days, the company’s Stochastic %K was 58.64% and its Stochastic %D was recorded 69.33%.
If we look into the earlier routines of ASLAN Pharmaceuticals Limited, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -11.33%. Additionally, trading for the stock in the period of the last six months notably deteriorated by 0.00%, alongside a downfall of -31.30% for the period of the last 12 months. The shares increased approximately by -1.10% in the 7-day charts and went down by 15.38% in the period of the last 30 days. Common stock shares were driven by 21.62% during last recorded quarter.